Houdini Bio’s stealth launch points to the infrastructure layer behind gene therapy
Houdini Bio emerged from stealth with £1.5M in pre-seed funding to build DNA sequence design infrastructure for genetic medicines.
Gene therapy is not only a drug-development story. It also depends on better tools for designing the DNA sequences behind those therapies.
What happened
UK biotech startup Houdini Bio emerged from stealth with about £1.5M in pre-seed funding.
The round was led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise VC. The company is building DNA sequence design infrastructure aimed at overcoming biological barriers that limit genetic medicines.
Why it matters
This is early-stage, but the product angle is interesting.
Houdini Bio is not only developing one therapy. It is building an upstream platform that could improve how genetic medicines are designed. That makes it more of an enabling technology story than a single-asset biotech bet.
The bigger picture
Biotech investors are increasingly interested in infrastructure that can make drug discovery and genetic medicine development more efficient.
If Houdini Bio can help design better DNA sequences for gene therapies, it could sit in a valuable part of the life-sciences stack: the tools that make future therapies easier to build.